These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 23370604

  • 1. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [Abstract] [Full Text] [Related]

  • 2. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
    Nassar HR, Zeeneldin AA, Helal AM, Ismail YM, Elsayed AM, Elbassuiony MA, Moneer MM.
    Asian Pac J Cancer Prev; 2015 Mar; 16(16):7237-42. PubMed ID: 26514517
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, De Iaco P, Di Battista M, Framarini M, Gazzotti F, Ghermandi C, Kopf B, Saponara M, Tauceri F, Vallicelli C, Verdecchia GM, Pinna AD.
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [Abstract] [Full Text] [Related]

  • 4. Treatment failure in endometrial carcinoma.
    Huang HJ, Tang YH, Chou HH, Yang LY, Chao A, Huang YT, Lin G, Liu FY, Chang TC, Lai CH.
    Int J Gynecol Cancer; 2014 Jun; 24(5):885-93. PubMed ID: 24819657
    [Abstract] [Full Text] [Related]

  • 5. Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?
    Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.
    Int J Gynecol Cancer; 2012 Jun; 22(5):786-91. PubMed ID: 22552832
    [Abstract] [Full Text] [Related]

  • 6. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
    Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J.
    Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
    Sabatier R, Calderon B, Lambaudie E, Chereau E, Provansal M, Cappiello MA, Viens P, Rousseau F.
    Int J Gynecol Cancer; 2015 Jun; 25(5):815-22. PubMed ID: 25768081
    [Abstract] [Full Text] [Related]

  • 8. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Cuesta-Guardiola T, Peregrin I, Mendizabal E, Lizarraga S, Ortiz-Quintana L.
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [Abstract] [Full Text] [Related]

  • 9. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [Abstract] [Full Text] [Related]

  • 10. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
    Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, Edwards RP.
    Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
    [Abstract] [Full Text] [Related]

  • 11. A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.
    Al-Badawi IA, Munkarah AR, Tulbah A, Babic II, Al Husaini H, Ahmad S.
    Int J Gynecol Cancer; 2013 Mar; 23(3):456-60. PubMed ID: 23360812
    [Abstract] [Full Text] [Related]

  • 12. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ, Bristow RE, Ryu HS.
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [Abstract] [Full Text] [Related]

  • 13. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Petrillo M, De Iaco P, Cianci S, Perrone M, Costantini B, Ronsini C, Scambia G, Fagotti A.
    Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
    [Abstract] [Full Text] [Related]

  • 14. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.
    Oncology; 2013 May; 84(3):158-65. PubMed ID: 23296063
    [Abstract] [Full Text] [Related]

  • 15. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H, Maurer KA, Nutter B, Rose PG.
    Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
    [Abstract] [Full Text] [Related]

  • 16. Individualized Treatment of Patients With Early-Stage Epithelial Ovarian Cancer After Incomplete Initial Surgery.
    Tu H, Xiong Y, Huang H, Huang Y, Wan T, Deng T, Liu J.
    Int J Gynecol Cancer; 2016 Jan; 26(1):73-81. PubMed ID: 26569056
    [Abstract] [Full Text] [Related]

  • 17. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H, Huang H, Huang QD, Li Z, Feng YL, Liu JH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [Abstract] [Full Text] [Related]

  • 18. Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
    Shaboodien R, Diamantis N, Blagden S, Gabra H, Agarwal R.
    Int J Gynecol Cancer; 2013 Mar; 23(3):481-7. PubMed ID: 23392404
    [Abstract] [Full Text] [Related]

  • 19. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
    Pradjatmo H, Pradjatmo H.
    Asian Pac J Cancer Prev; 2016 Mar; 17(4):1881-6. PubMed ID: 27221870
    [Abstract] [Full Text] [Related]

  • 20. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
    Rosendahl M, Høgdall CK, Mosgaard BJ.
    Int J Gynecol Cancer; 2016 May; 26(4):680-7. PubMed ID: 26937751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.